In this paper we determine the ability of a new multivalent vaccine, comprising core canine viral and four leptospira serovars vaccine antigens, and containing a canine parvovirus type 2b strain to induce cross-neutralising antibody responses to CPV-2, CPV-2a and CPV-2c.